Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 17, 2008 Brian Orelli	EPIX's Epic Oops The EPIX clinical trial data on their Alzheimer's medication wasn't as positive as it first appeared.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool June 21, 2007 Brian Lawler	Panacos Validates Itself Panacos releases more clinical trial results for an exciting drug. Investors, take note.
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool January 24, 2005 Rich Duprey	No Taking Chances With Reminyl Johnson & Johnson's daffodil-extract Alzheimer's treatment yanked from market. Shares are off only 1% or so.
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool March 17, 2006 Rich Duprey	Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool August 27, 2007 Rich Duprey	Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo.
The Motley Fool May 16, 2007 Mike Havrilla	Waiting on Memory Pharmaceuticals The small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool May 15, 2007 Mike Havrilla	A Heads-Up on TorreyPines The drugmaker's tezampanel for migraines shows promise after some trials. Investors, take note.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
The Motley Fool April 3, 2009 Brian Orelli	Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug.
BusinessWeek March 5, 2007 Gene G. Marcial	What Glaxo Saw In Epix Some pros think EPIX pharmaceuticals' stock will more than double in a year.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool November 2, 2006 Rich Duprey	Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
The Motley Fool April 17, 2007 Rich Duprey	Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors?
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
American Family Physician October 1, 2003 Vincent W. Delagarza	Pharmacologic Treatment of Alzheimer's Disease: An Update Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons. Drugs that inhibit the degradation of acetylcholine within synapses are the mainstay of therapy.
American Family Physician August 15, 2000 Matthew Neff	Conference Highlights Investigational Alzheimer's Drug Improves Memory... Indoor Allergens Are Closely Linked with Allergic Disease and Asthma... Paroxetine Is Effective Treatment For Anxiety in Patients with GAD... Treatment with Citalopram Prevents Recurrent Depressive Episodes...
Pharmaceutical Executive July 1, 2006 Derek Lowe	What You Need to Know About Adaptive Trials A handful of new statistical techniques and clinical-trial designs will let you change the way you run your business. Here's your guide to the basics.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
The Motley Fool January 14, 2005 W.D. Crotty	An FDA OK That Hurts EPIX Pharmaceuticals gets a qualified "yes" from the FDA, sending its stock tumbling.
The Motley Fool April 12, 2004 Brian Gorman	Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors.
The Motley Fool January 21, 2004 Alyce Lomax	Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit.
The Motley Fool May 23, 2006 Rich Duprey	Eisai Has a Yen for Profits With new formulations for its current drugs planned for release, expansion of its blockbuster drug Aricept possible, and with a few new drugs in the pipeline, the Japanese pharmaceutical is poised to continue churning out record revenues and earnings that investors won't soon forget.
American Family Physician June 15, 2002 Jeffrey L. Cummings	Guidelines for Managing Alzheimer's Disease: Part II. Treatment Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. Patient symptoms and care needs change as Alzheimer's disease progresses.
American Family Physician December 15, 2006 Epstein et al.	Newer Agents for the Management of Overactive Bladder The availability of three newer anticholinergic drugs increases the pharmacologic armamentarium for the treatment of overactive bladder. Caution is required with each of these agents, particularly in patients with contraindications to anticholinergic therapy.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
Bio-IT World May 2006 Kevin Davies	Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials.
American Family Physician December 1, 2000 Sharon Scott Morey	Guidelines on Migraine Recommendations for Specific Prophylactic Drugs...
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.